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The GEF Trio controls endothelial cell size and
arterial remodeling downstream of Vegf signaling
in both zebrafish and cell models
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Arterial networks enlarge in response to increase in tissue metabolism to facilitate flow and
nutrient delivery. Typically, the transition of a growing artery with a small diameter into a
large caliber artery with a sizeable diameter occurs upon the blood flow driven change in
number and shape of endothelial cells lining the arterial lumen. Here, using zebrafish embryos
and endothelial cell models, we describe an alternative, flow independent model, involving
enlargement of arterial endothelial cells, which results in the formation of large diameter
arteries. Endothelial enlargement requires the GEF1 domain of the guanine nucleotide
exchange factor Trio and activation of Rho-GTPases Rac1 and RhoG in the cell periphery,
inducing F-actin cytoskeleton remodeling, myosin based tension at junction regions and focal
adhesions. Activation of Trio in developing arteries in vivo involves precise titration of the
Vegf signaling strength in the arterial wall, which is controlled by the soluble Vegf
receptor Flt1.
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The arterial vascular network distributes blood flowthrough the body, a process crucial for sustaining organfunction and homeostasis. During embryonic develop-
ment arterial networks enlarge and expand to meet the
increasing metabolic demand of the growing and differentiating
tissue. Also in ischemic cardiovascular diseases, revasculariza-
tion, and regeneration of hypoperfused organs involve adap-
tations of the arterial system1,2. Selective targeting of the
arterial growth process, and in particular creating arteries with
a structurally large diameter to enhance flow conductance and
relief hypoxia, is considered therapeutically relevant for treating
patients with ischemic cardiovascular diseases1,2. The mole-
cular and cellular mechanisms controlling arterial diameter are
only partly understood but involve interactions between blood
flow and endothelial cells, and BMP-Smad signaling controlling
distinct endothelial cell behaviors during the vascular remo-
deling process3–5.
An increase in flow promotes endothelial cell proliferation and
migration collectively facilitating the transition of a small caliber
vessel segment, with only few endothelial cells, into a larger
caliber arterial segment, with many endothelial cells6–9. Flow
activates the Akt-PI3-kinase signaling pathway responsible for
endothelial proliferation. In addition, flow activates the BMP9-
Alk1-Eng-Smad4 signaling pathway, which restricts flow-induced
Akt activation and promotes endothelial quiescence5,6,10–14. The
extent of diameter remodeling of arteries is determined by the
amount of flowing blood and the shear stress setpoint15. Blood
flow creates frictional forces exerted on endothelial cells, termed
shear stress. Shear stress level has to be kept within strict
boundaries to maintain endothelial quiescence and vessel stabi-
lity3. A sustained increase in blood flow and shear stress promotes
outward remodeling of the arterial lumen, resulting in a return of
shear stress levels to the original setpoint. Vegf receptor-3/Flt4 is
a component of the endothelial junctional mechanosensory
complex, and acts as a determinant of the shear stress
setpoint16,17. Lowering Flt4 expression and increasing the shear
stress setpoint causes arteries to narrow thereby allowing shear
stress to return to the setpoint16. In addition, increases in flow,
after causing an initial diameter increase, have been shown to
induce vessel contraction mediated via endothelial cell shape
changes10. The transforming growth factor beta co-receptor
Endoglin regulates vessel contraction, and loss of endoglin results
in enlarged endothelial cells and blood vessel diameter in
response to flow increases10. In adult pre-existing collateral
arteries, flow-dependent arterial outward remodeling also
involves activation of NFκB and inflammatory pathways in
endothelial cells, leading to the recruitment of monocytes/mac-
rophages that assist with remodeling by secretion of matrix
metalloproteinases, and growth factors18,19. In gridlock mutant
zebrafish embryos, macrophages contribute to flow driven out-
ward remodeling of aortic collaterals, suggesting a devel-
opmentally conserved role for macrophages in arterial
remodeling20.
Cell shape is determined by the activity of small Rho GTPases.
Their activity contributes to maintaining an equilibrium between
the forces providing centripetal tension and forces ensuring cell
spreading and avoidance of cell collapse21–23. Here we show that
in endothelial cells, the guanine nucleotide exchange factor Trio,
and activation of the small GTPases Rac1 and RhoG, trigger F-
actin remodeling events in the endothelial cell periphery,
increasing endothelial cell size. Arterial-specific expression of
Trio in vivo augments endothelial cell size, resulting in functional
arteries with a structurally larger lumen diameter, without change
in endothelial cell numbers. Activation of Trio in vivo requires
subtle fine-tuning of local arterial Vegf-Kdrl signaling levels,
which is achieved by arterial Flt1 acting as a Vegf trap. Genetic
targeting of the local arterial Flt1-Vegf balance results in endo-
thelial cell enlargement, and significant outward arterial diameter
remodeling, even during low flow conditions. Increases in vessel
diameter reduce the resistance to flow. Trio-induced endothelial
shape changes, and diameter remodeling in response to Vegf, may
therefore aid to fine-tune local flow distribution in response to
changes in tissue metabolism or hypoxia.
Results
Arterial Flt1 determines arterial diameter. Vegf is an attractive
candidate for targeting arterial caliber as it controls key aspects of
arterial development1,24,25, and is capable of activating small
Rho-GTPases. Yet, beyond a narrow therapeutic window Vegf
may induce adverse side-effects such as vessel overgrowth, e.g.,
hemangioma formation, and increased vessel permeability. How
to deliver Vegf without deleterious side-effects is still an out-
standing issue26. To fine-tune the spatio-temporal delivery of
Vegf needed to obtain large arteries, we examined formation of
arterial networks in the trunk of developing zebrafish embryos
using different vegfaa gain of function scenarios.
We first employed transgenic embryos with constitutive or
inducible expression of vegfaa under control of the somite
muscle-specific 503unc promoter27 (here termed vegfaamusc;
Fig. 1a, b; Supplementary Fig. 1a–d). Constitutive vegfaa over-
expression increased endothelial cell number and disrupted the
arterial vasculature, abrupting blood flow perfusion when
compared to wild-type (WT) (Fig. 1a, b). Similar results were
obtained upon inducible vegfaa overexpression (Supplementary
Fig. 1b, d, e–w). Because such vegfaa transgenic approaches
resulted in Vegfaa overdose inappropriate for targeting the
diameter of arteries, we next aimed at obtaining more subtle
changes by manipulating Vegf protein bioavailability, which is
determined by the Vegf decoy receptor Flt1.
Flt1 has a very high affinity for Vegf and mainly acts as a Vegf
trapping receptor, limiting Vegf bioavailability and signaling
through Kdrl28,29. Conversely, ablating flt1 or displacing Flt1-
trapped Vegf produces a Vegf gain-of-function scenario, with
endogenous production of Vegf. We hypothesized that Flt1 can
be used as a vehicle to deliver Vegf directly into growing arteries.
For this approach to work efficiently, Flt1 protein must be
expressed in close proximity to the Vegf signaling receptor Kdrl
on arterial endothelium. We found that this is indeed the case
(Fig. 1c–g). The developing arterial intersegmental vessels (aISV)
displayed flt1 promoter activity (Supplementary Fig. 2a–c) and
expressed both flt1 isoforms; the membrane bound flt1 (mflt1)
and soluble flt1 (sflt1) (Supplementary Fig. 2d, e). To determine
Flt1 protein distribution, we generated a knockin line, harboring
two HA tags in exon 3 of the endogenous flt1 locus, which labeled
both mFlt1 and sFlt1 (Supplementary Fig. 2f). Immune staining
of the transgene demonstrated Flt1 protein expression in the
developing aISVs (Fig. 1c, d). To substantiate the distribution of
the secreted, soluble Flt1 isoform around developing arteries, we
furthermore examined protein distribution in a transgenic line
expressing an engineered HA-tagged sflt1 transgene with an
inactive Vegfaa binding domain (Tg(flt1enh:sflt1_Δ7-HAHA)ka612,
Supplementary Fig. 2g–n). Immune staining showed sFlt1 protein
co-localizing with kdrl in arterial endothelium (Fig. 1e-g;
Supplementary Fig. 2l–n). Transgenics with tagged wild-type
sflt1-HAHA could not be used, because gain of wt-sflt1-HAHA
decreased local Vegf29 and inhibited aISV formation, thus
rendering this experiment uninterpretable (Supplementary
Fig. 2i–k).
Arterial ISVs, which express the Flt1 protein, are juxtaposed to
Vegf-producing cells in developing somites24. Ablation of flt1,
thereby creating a Vegfaa gain of function scenario29, resulted in
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a significant increase of aISV diameter (Fig. 1h-l). A similar result
was obtained with a flt1 targeting morpholino29 (Fig. 1m, n).
High levels of the Flt1 ligands Plgf or Vegfb cause displacement
of Vegf from Flt1 to Kdrl, creating a local Vegfaa gain of function
scenario. In line with this competition model, plgf and vegfba
gain of function transgenics (Tg(503unc:eGFP-p2A-plgf) here
termed plgfmusc; and Tg(503unc:eGFP-p2A-vegfba) here termed
vegfbamusc) showed significantly increased arterial lumen dia-
meters (Fig. 1j, k, l; Supplementary Fig. 2o, p). On average aISV
diameter increased 1.9 and 2.0 fold in plgfmusc and vegfbamusc
embryos respectively (Fig. 1l). The larger aISVs were functional
and not leaky (Fig. 1o–q; Supplementary Fig. 2q–t; Supplemen-
tary Movies 1–3). Membrane bound mFlt1 signaling was not
required for diameter growth in this setting; aISVs were
significantly larger in mflt1−/− mutants (Fig. 2a–d), and
overexpression of plgf in mflt1−/− mutants still resulted in a
pronounced increase in arterial diameter when compared to WT
or mflt1−/− diameter (Fig. 2a–d).
While both loss of flt1 and plgf gain of function induce a Vegf
gain of function scenario, one component that may contribute to
the difference in arterial diameter between plgfmusc embryos and
flt1−/− mutants involves the spatial distribution of arterial Flt1
and Kdrl receptors. In plgfmusc, Flt1, and Kdrl are both expressed
in the same arterial ECs (Fig. 1g, Supplement Fig. 2u). Such
expression pattern is absent in flt1−/− mutants as Flt1 is not









































































































































































































































Fig. 1 Arterial Flt1 determines vessel lumen dimensions. a, b In vivo confocal imaging of trunk vascular architecture in WT (a) and vegfaamusc transgenic
embryos (b). Note disrupted vascular development in vegfaamusc transgenics. c, d Whole mount immune staining with anti-HA antibody in TgTm
(flt1_E3_HAHA)ka611 embryos at 32 hpf (c) and 48 hpf (d) to show Flt1 protein distribution. Arrows indicate aISVs and box shows zoom. e–g
Immunestaining with anti-HA antibody showing sFlt1 protein distribution in Tg(flt1enh:sflt1_Δ7-HAHA)ka612; Tg(kdrl:hsa.HRAS-mcherry)s916 double transgenic
embryos. aISV express sFlt1 protein (green; e); kdrl is shown in red (f) and merge shows colocalization of sFlt1 and kdrl in aISV (g, blue arrows). The white
squared inset in e indicates control staining. h–k Confocal imaging of aISV in WT (h), flt1−/− mutant, flt1ka601 (i), plgf GOF transgenic plgfmusc (j), and vegfba
GOF transgenic vegfbmusc (k). Upper panels show overview; lower panels show detail of red boxed area. l Quantification of aISV diameter for indicated
genotype; mean ± s.e.m, unpaired two-sided students t-test, n= 18, 16, 16, 10 aISVs per genotype. ***p < 0.001. m Confocal imaging of aISV in WT injected
with flt1 targeting morpholino. Area indicated by the red dotted box in the upper panel is displayed at higher magnification in the lower panel. n Relative
aISV diameter change in embryos injected with flt1 targeting morpholino (WT= 100%). mean ± s.e.m, unpaired two-sided students t-test, n= 20, 25 aISVs
for indicated scenario, ***p < 0.001. o, p Imaging of plasma extravasation in WT and plgfmusc (n= 14, 16 embryos) injected with 70kD Dextran Texas-Red
from 3 biologically independent experiments. q Quantification of images in o,p. mean ± s.e.m; unpaired two-sided students t-test, n= 6, 8 embryos per
indicated group. ns, not significantly different. Scale bar, 50 μm in a–g, o, p; 25 µm in h–k, m. aISV intersegmental artery, DA dorsal aorta, PCV posterior
cardinal vein. hpf hours post fertilization, MO morpholino, GOF gain of function.
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accounts for the observed difference, the model predicts that
reducing flt1 expression in plgfmusc, should annihilate the
difference between plgfmusc and flt1−/− mutants. Nevertheless,
arteries in plgfmusc transgenics injected with a flt1 targeting
morpholino should still show some degree of arterial diameter
growth as the knockdown of flt1 itself induces a vegfaa gain-of-
function scenario, similar as in flt1−/− mutants. We tested these
assumptions, and in-line with our hypothesis we indeed found
that knockdown of flt1 in plgfmusc embryos reduced arterial
diameter growth, to the levels observed in flt1−/− mutants
(Fig. 2e–h).
Arterial diameter growth requires Vegf receptor-2 signaling.
Our data support the model in which excessive Plgf displaces
trapped Vegfaa from arterial Flt1, thereby allowing the released
free Vegfaa to bind arterial Kdrl receptors to induce signaling. In-
line with Vegfaa-Kdrl signaling in plgfmusc embryos, we found
that inhibiting Kdrl signaling or reducing vegfaa using a low dose
vegfaa ATG targeting morpholino reduced lumen diameter
growth in plgfmusc (Fig. 3a–f). Arterial ISVs express kdrl and the
Vegf receptor-3, flt4, which can regulate Vegf receptor-2 signaling
output30. Genetically ablating flt4 or morpholino-mediated
knockdown of flt4 did not affect arterial diameter growth in
plgfmusc or flt1 loss of function embryos (Fig. 3g–k; Supplemen-
tary Fig. 3a–g). As Plgf may bind to neuropilin-1 receptors
we examined nrp1 mutants. Plgf increased aISV diameter in
nrp1a−/− mutants (Supplementary Fig. 3h). Taken together these
data indicate that Vegf-Kdrl is the main signaling pathway
accounting for diameter growth in plgfmusc.
Developing aISVs in plgfmusc were enlarged prior to formation
of a functional perfused trunk vascular network (Fig. 3l–n). To
rule out increased flow as a trigger for Plgf-induced arterial
remodeling, we next exposed aISVs of plgfmusc embryos to low
flow conditions. To reduce heart rate and trunk perfusion, we
treated WT and plgfmusc embryos with the L-type calcium
channel blocker nifedipine10,16 (Fig. 3o–r). WT embryos exposed
to nifedipine showed reduced aISV and aorta diameter (Fig. 3o–r;
Supplementary Fig. 4a–d). However, plgfmusc embryos exposed to
nifedipine still showed a significant increase in aISV diameter
when compared to WT with normal flow, or WT with nifedipine
(Fig. 3r). Similar observations were made in tnnt2 morphants
(Fig. 3s–v; Supplementary Fig. 4e–g). Reducing cardiac contrac-
tility by knocking down cardiac troponin T2 (tnnt2) is an
established approach for creating a silent heart and block trunk
perfusion (Supplementary Fig. 4h–l). Tnnt2 morphants showed a
reduced aISV size and aortic diameter (Fig. 3s–v; Supplementary
Fig. 4h–k). However, despite loss of flow, aISV size was still larger
in plgfmusc embryos injected with tnnt2 targeting morpholino,
when compared to WT with flow, or WT injected with tnnt2
morpholino (Fig. 3s–v); while tnnt2 morphants showed deficits in
lumen formation (Fig. 3t), plgfmusc—tnnt2 morphants showed a
clear lumen on confocal sections of 3D stacks (Fig. 3u).
As mouse studies attribute the proarteriogenic effect of Plgf to
activation of mFlt1 signaling in macrophages, we decided to
investigate Plgf in a macrophage loss-of-function model31.
Reducing macrophage differentiation (using a triple morpholino
knockdown of pu.1, gcsfr, and irf8) had no effect on aISV
diameters in plgfmusc gain of function embryos (Supplementary
Fig. 5a–l). Taken together, our data suggest that Plgf-induced
aISV remodeling is neither triggered by increased shear stress nor
macrophages.
Endothelial size contributes to diameter remodeling in vivo.
Theoretically, outward arterial diameter remodeling in the
dmflt1–/–WT mflt1–/– + plgf musc
48 hpf
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Fig. 2 mFlt1 is not required for plgf-induced arterial diameter growth. a–c In vivo confocal imaging of aISV in WT (a); mft1−/− mutant, mfltka605, (b);
mft1−/− combined with plgf gain of function plgfmusc (c); n= 58,64 and 57 aISVs per genotype derived from three autonomous experiments. The areas indicated
by the red dotted boxes are displayed at higher magnification in the lower panels. d Quantification of images in a–c. Mean ± s.e.m, unpaired two-sided students
t-test, n= 7,13, and 24 aISVs for indicated scenario. **p=0.0051, ***p < 0.001. Note: significantly increased aISV diameter in mflt1−/−+plgfmusc scenario.
e–g In vivo confocal imaging of aISV in plgfmusc (e), plgfmusc concomitant with morpholino knock-down of flt1 (f; plgfmusc+ flt1-MO), flt1−/− mutant, flt1ka601 (g).
The areas indicated by the red dotted boxes are displayed at higher magnification in the lower panels. h Quantification of images in e–g. mean ± s.e.m, unpaired
two-sided students t-test, n= 40,19, and 13 aISVs for indicated scenario. ns not significant, **p < 0.01. Scale bar; 25 µm in all panels. hpf hours post fertilization,
aISV intersegmental artery, MO morpholino.
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developing aISV can be achieved in three ways: by having more
endothelial cells, larger endothelial cells or a combination of both.
We detected the combination of both: more and enlarged endo-
thelial cells in aISVs upon plgf gain-of-function when compared
to WT (Fig. 4a–e; Supplementary Fig. 6a–f; Supplementary
Movies 4 and 5). Analyses of life-act reporter embryos showed a
significant increase in total endothelial cell surface area and in
surface area expansion rate, when comparing plgfmusc embryos to
WT (Fig. 4e; Supplementary Fig. 6g; Supplementary Movies 4 and
5). We reasoned that RhoGTPase activity and changes in F-actin
remodeling could contribute to the in vivo phenotypic changes in
endothelial cell shape.
To block F-actin polymerization, we administered the actin
polymerization inhibitor Latrunculin B (LatB)32 in vivo. LatB
significantly reduced aISV diameter growth in plgfmusc embryos
when compared to vehicle treated plgfmusc embryos (Fig. 4f;
Supplementary Fig. 6h–p). Major aspects of intracellular F-actin
dynamics are regulated through the small Rho GTPases family,
including Rac1 and RhoG33. The Rac1 inhibitor CAS 1177865-
17-6 significantly inhibited aISV diameter expansion in plgfmusc
embryos (Fig. 4f; Supplementary Fig. 6h–p). The RhoGEF (Rho-
Guanine nucleotide Exchange Factor) Trio is well recognized for
its ability to activate Rac1 and RhoG34 through its GEF1 domain.
ITX3, a selective inhibitor of the Trio N-terminal RhoGEF
e
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(GEF1) domain35 significantly reduced the outward remodeling
response of aISVs (Fig. 4f; Supplementary Fig. 6h–p). To further
substantiate the contribution of Trio in this setting we examined
loss of Trio in WT and plgfmusc embryos using a morpholino
approach (Fig. 4g–t; Supplementary Fig. 7a–c). Morpholino-
mediated knockdown of Trio resulted in a dose-dependent
decrease of endothelial cell size and aISV diameter in WT and
plgfmusc embryos (Fig. 4m, t).
Endothelial enlargement requires the GEF1 domain of Trio.
Rho GTPases control actin reorganization, and GEFs like Trio
activate Rho GTPases by promoting their exchange of GDP for
GTP. Trio is a unique Rho GEF, because it has two separate GEF
domains, GEF1 and GEF2, that control the GTPases RhoG/Rac1
and RhoA, respectively36. To substantiate which GEF domain of
Trio is functionally relevant for cell enlargement in our setting,
we performed gain-of-function experiments with Trio deletion
constructs37. In vitro overexpression of a truncated Trio form
containing the spectrin domain and GEF1 domain (termed
TrioN), but lacking the GEF2 domain, resulted in significantly
larger endothelial cells compared to control-transfected cells
(Fig. 5a–d, quantification in Fig. 5g). In further support of
functional requirement of the GEF1 domain we found that
overexpression of the GEF1 domain only also induced endothelial
cell enlargement (Fig. 5e,f quantification in Fig. 5g). Besides full
length Trio, 4 additional Trio-GEF1 containing isoforms (Trio-A,
B, C, D) arising from alternative splicing have been described38.
In HUVEC, all GEF1 containing isoforms were detectable but full
length Trio was the most abundant Trio form (Supplementary
Fig. 8a). The Trio-B isoform is truncated at the C-terminus and
similar to TrioN only contains the GEF1 domain. In support of
the GEF1 domain, endothelial overexpression of Trio-B increased
endothelial size (Supplementary Fig. 8b).
The GEF1 domain of Trio can activate both Rac1 and RhoG.
Endothelial cells transfected with constitutively active Rac1, or a
photo-activatable Rac1 probe39 (Rac1-PA-WT) that was activated
by light showed a significantly larger size when compared to
mCherry-expressing control cells (Fig. 5h–l), whereas a catalytic-
dead mutant of the photo-activatable Rac1 probe (Rac1-PA-
C450A) failed to induce a cell size change upon exposure to light
(Fig. 5h–l). We found no evidence for a functional role of the
Rac1B splice-isoform (Supplementary Table 1; Supplementary
Fig. 8c–g). Endothelial overexpression of a dominant active RhoG
form (GFP-RhoG-Q61L) significantly increased endothelial cell
area (Fig. 5m). Conversely, silencing of Rac1 or RhoG in
endothelial cells overexpressing TrioN significantly reduced the
TrioN-induced cell size increase (Fig. 5n–p; Supplementary
Fig. 8h). Unfortunately, simultaneous silencing of both Rac1
and RhoG in TrioN expressing cells resulted in massive
endothelial cell death.
The in vivo data suggest that Vegf signaling can activate Trio.
Exposing endothelial cells to VEGF in vitro, triggered a rapid and
transient activation of Rac1 (Supplementary Fig. 8i–l). Activation
of Rac1 involved Trio as shRNA-mediated silencing of Trio using
two different shRNAs reduced VEGF-induced Rac1 activation
(Supplementary Fig. 8i–l). Besides Trio, there are a number of
other known regulators for Rac1, including Tiam1, and multiple
regulators may coordinate in regulating the function of Rac1 in
this context. In endothelial cells overexpressing TrioN, we
observed that Tiam1 was expressed in junctional regions, as
opposed to the more cytosolic localization observed in control-
transfected cells (Fig. 5q–v). Endothelial overexpression of Tiam1
resulted in larger endothelial cells, similar to the effects observed
upon overexpression of TrioN (Fig. 5w). Combining TrioN and
Tiam1 overexpression had no additive effect on increasing EC
size when compared to TrioN alone (Fig. 5w). These data suggest
that one part of cell enlargement may require careful spatial
positioning of GEFs, and activation of RhoGTPases in junctional
regions.
Trio activates Rac1 in junctional regions. Using a Rac1 FRET-
based biosensor we found that Trio activated Rac1 in particular at
endothelial cell junctional regions (Fig. 6a, b). TrioN and Trio-
GEF1 were equally potent in activating Rac1 at junction regions
(Fig. 6c, d; Supplementary Fig. 9a–c). Mutating the functional
GEF1 domain in TrioN (TrioNmut40) abrogated Rac1 activation
(Fig. 6c, d; Supplementary Fig. 9d). TrioN-transfected cells
showed formation of lamellipodia, and enlargement of the
endothelial cells along the front of the lamellipodia extensions
(Supplementary Fig. 9e–g; Supplementary Movie 6). Control-
transfected cells also showed lamellipodia formation, but in
control cells these lamellipodia more often retracted and no
subsequent enlargement was observed (Supplementary Fig. 9h–j;
Supplementary Movie 7). TrioN significantly increased the life-
time of lateral lamellipodia when compared to transfected cells;
accordingly the number of protrusions per hour was reduced in
TrioN-transfected cells (Fig. 6e, f). After 17 h post-TrioN trans-
fection, no additional enlargement was observed and the VE-
Cadherin expression pattern was reminiscent of a honeycomb
structure, suggestive of a force-equilibrium between the inter-
acting cells41.
Actomyosin complexes and myosin-II-mediated contractility
contribute to tension development42,43. Using GFP-tagged
Myosin II we found that Myosin II localized on F-actin bundles
throughout the cell but was most prominently present on
junctional F-actin bundles upon TrioN transfection (Fig. 6g, h).
Fig. 3 Vegfaa—Vegf receptor-2/Kdrl signaling drives outward arterial lumen remodeling. a–d aISV in WT (upper panels) and plgfmusc embryos (lower
panels) treated with DMSO vehicle - control (a), low dose Vegf-R2 inhibitor (b), high dose Vegf-R2 inhibitor (c), or vegfaa ATG targeting morpholino (d).
Red dotted box is displayed at higher magnification in panel below. e Quantification of aISV diameter at 50 hpf upon R2 inhibition. Mean ± s.e.m, one-way
ANOVA, and post-hoc bonferroni, n= 18, 20, 20, 15, 20, 20 aISVs for indicated scenarios. **p= 0.0026, ***p < 0.001. f Quantification of aISV diameter at
48 hpf upon morpholino-mediated knockdown of vegfaa. Mean ± s.e.m, one-way ANOVA, and post-hoc bonferroni, n= 15, 22, 14, 28 aISVs for indicated
scenarios. ***p < 0.001. g–j In vivo confocal imaging of WT (g), flt4−/− mutant, flt4mu407(h), flt4−/− mutant injected with flt1 ATG targeting morpholino
(i), flt4−/− mutant injected with plgfmusc plasmid (j). k Quantification of images in g–j. Left panel, absolute aISV diameter (n= 21, 16, 42, 34 aISVs per
indicated genotype). Right panel, aISV diameter change relative to WT. Mean ± s.e.m, unpaired two-sided students t-test. ns not significant, ***p≤ 0.001.
l,m In vivo confocal imaging of developing aISVs prior to the onset of aISV perfusion in WT (l) and plgfmusc embryos (m). Note: larger aISV prior to onset of
flow in plgfmusc. n Quantification of images in l, m. Mean ± s.e.m, unpaired two-sided students t-test, n= 16 aISVs/group. ***p < 0.001. o–q Imaging of WT
(o), WT treated with L-type calcium channel blocker nifedipine (p), and plgfmusc treated with nifedipine (q). r Quantification of images in o–q. Mean ± s.e.m,
unpaired two-sided students t-test, n= 11, 20, and 15 aISVs per treatment group. ***p < 0.001. s–u Confocal cross-section to show lumen dimensions of
aISV in WT (s), WT injected with tnnt2 targeting morpholino (t), and plgfmusc embryo injected with tnnt2 targeting morpholino (u). v Quantification of
images in s–u. Mean ± s.e.m, unpaired two-sided students t-test, n= 20 aISVs per group. ***p < 0.001. Scale bar: 25 μm in all images. aISV intersegmental
artery, MO morpholino, hpf hours post fertilization, RI remodeling index, tnnt2 cardiac muscle troponin T2.
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Also, the majority of active myosin, distinguished by staining for
mono-phosphorylated myosin light chain S19, localized strongly
at the junction region upon TrioN overexpression (Fig. 6i, j). In
addition, we observed that fully di-phosphorylated myosin light
chain (T18/S19) localizes even more specifically to junctional F-
actin bundles (Fig. 6k, l). Inhibition of myosin activity from 1 h
after TrioN transfection significantly abrogated Trio-induced
endothelial cell size enlargement (Supplementary Fig. 9k–m).
Inhibiting myosin activity in already enlarged endothelial cells
resulted in the formation of gaps in particular at tri-cellular
junctions (Supplementary Fig. 9n, o).
We next reasoned that Trio-induced changes in myosin-II and
cytoskeletal remodeling affect the tension distribution along the
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junctional, cortical, and central F-actin bundles, in TrioN and
control-transfected endothelial cells by laser-ablating single
F-actin bundles (Fig. 6m–s). As a read out for local tension,
we measured the recoil of the actin structures upon ablation
(Fig. 6p)44. Transfection of TrioN only increased the tension on
junctional actin bundles, and not on cortical or central bundles
(Fig. 6q–s). Taken together, these findings suggest that TrioN
gain-of-function preferentially augmented tension at junctional
F-actin bundles.
VE-Cadherin is not required for Trio-induced EC enlargement.
Trio interacts with VE-Cadherin45, and endothelial cells gain
stability by making contacts with neighboring cells through VE-
cadherin–based cell–cell junctions. Endothelial monolayers
transfected with TrioN in vitro showed augmented junctional
integrity as indicated by increased electrical cell-substrate impe-
dance (ECIS) (Fig. 7a). Interestingly, this increase in junctional
strength was independent of VE-Cadherin, as TrioN over-
expression augmented electrical cell-substrate impedance even in
the absence of VE-Cadherin (Fig. 7b, c). Other junctional mole-
cules may compensate for loss of VE-Cadherin. We found no
substantial changes in N-Cadherin expression at junctions in
endothelial cells in which overexpression of TrioN was combined
with silencing of VE-Cadherin (Supplementary Fig. 10a–l).
To test if VE-Cadherin-based cell–cell junctions are function-
ally relevant for the TrioN-induced enlargement of endothelial
cells, we overexpressed TrioN while simultaneously silencing
endothelial VE-Cadherin (Fig. 7d-m). Loss of VE-Cadherin had
no significant impact on TrioN-induced endothelial cell enlarge-
ment (Fig. 7m). To test if coordination between adjacent
endothelial cells is critical for endothelial enlargement in vitro,
we performed mosaic experiments by mixing TrioN overexpres-
sing endothelial cells with control-transfected endothelial cells
(Supplementary Fig. 10m), and compared cell size with a scenario
in which all (neighboring) cells were expressing TrioN (homo-
geneous expression scenario). In both the mosaic and in the
homogeneous scenario we find increased EC size in TrioN
overexpressing cells (Fig. 7n). The magnitude of cell size increase
was not significantly different between the two scenarios (Fig. 7n).
Endothelial cells anchor to the extracellular matrix (ECM)
through focal adhesions. In endothelial lamellipodia extensions,
anchoring to the ECM is necessary for the buildup of tractional
forces that regulate forward extension and cell shape. We
hypothesized that to maintain their shape, the enlarged
endothelial cells have to be able to stably anchor to the ECM.
In line with this, we found that TrioN massively increased the
number of focal adhesions, in particular near cell–cell junctions,
as judged by phosphorylated Paxillin staining (Fig. 7o–s). TrioN
overexpressing cells furthermore showed a shift in the expression
of α5 Integrin and β1 Integrin toward junctional regions
(Fig. 7t–w).
Trio augments EC size and arterial diameter in vivo. To test if
Trio can augment endothelial cell size and arterial dimensions
in vivo in zebrafish embryos, we generated a transgenic line and
overexpressed TrioN under the control of the flt1enh promoter (Tg
(flt1enh:GFP-TRION) here termed flt1enh:TrioN) (Fig. 8a–g). The
flt1enh promoter is mainly active in arterial ISVs. Overexpression
of TrioN in vivo resulted in significantly larger aISVs (Fig. 8e)
without affecting endothelial cell numbers (Fig. 8g). Instead, and
in-line with our in vitro observations, TrioN increased endothelial
surface area in aISVs (Fig. 8f). The aISV diameter increase was
therefore solely attributed to larger endothelial cells. The larger
aISVs upon TrioN overexpression were perfused and nonleaky as
evidenced from dextran extravasation analyses (Supplementary
Fig. 11a–d).
We next overexpressed TrioN under control of the flt1enh
promoter in plgfmusc embryos (Fig. 8h–o). Overexpression of
TrioN in plgfmusc embryos resulted in significantly larger aISVs
and endothelial surface area, when compared to plgfmusc alone
(Fig. 8m, n, o, u). On an average, combining plgf and TrioN
resulted in 2.5-fold larger aISV diameters (Fig. 8o); whereas in
plgfmusc embryos the increase was 2-fold (Fig. 8o). The enlarged
aISVs in plgfmusc+ TrioN gain of function embryos were actively
perfused (Supplementary Movie 8). Overexpression of TrioNmut
(TrioN with inactive GEF1 domain) in plgfmusc transgenics failed
to produce any additive increase in aISV diameter or endothelial
surface area (Fig. 8o). Taken together, these data suggest that
combining plgf with artery specific Trio transgenic gain-of-
function results in arteries having multiple enlarged endothelial
cells, which additively facilitate the arterial outward lumen
remodeling.
We furthermore found that VE-Cadherin was not required for
TrioN-induced endothelial cell size increase in vivo. Over-
expression of TrioN in aISVs of ve-cadherin morphants (cdh5-
MO) or ve-cadherin−/− mutants augmented endothelial area at a
similar magnitude as observed in TrioN gain-of-function embryos
with intact ve-cadherin expression (Fig. 8p–t; Supplementary
Fig. 11e).
We next examined if the effect of Trio on arterial diameter
in vivo and cell size in vitro is conserved when using alternative
vascular promoters or endothelial cells derived from different
anatomical origins, respectively (Supplementary Fig. 11f–h). The
kdrl and fli1a promoter are ubiquitously expressed in endothelial
cells of the zebrafish embryo trunk vasculature. For both kdrl and
fli1a we observed significantly increased aorta and aISV
Fig. 4 Plgf-induced arterial diameter growth requires the Rho GEF Trio. a, b endothelial cell (EC) nuclei distribution in green (eGFP) during aISV
formation in WT (a) and in plgfmusc embryos (b). ECs derived from migration events numbered in yellow, from proliferation events in purple.
c Quantification of migration (yellow) and proliferation (purple) events during aISV formation; mean ± s.e.m, unpaired two-sided students t-test, n= 10,11
aISVs for indicated genotype. *p= 0.0190, ***p < 0.001. d Time-lapse imaging in Tg(fli1a:lifeactEGFP)mu240 showing endothelial actin in aISV of WT (upper
panels) and plgfmusc embryos (lower panels). Red box in the left panel at higher magnification in the right panels. Arrowheads at 41hpf delineate an
individual EC. e EC surface area changes in WT (blue circles) and plgfmusc embryos (red squares); mean ± s.e.m, unpaired two-sided students t-test, n= 6
ECs for each genotype. f Left panel, arterial ISV diameter in plgfmusc embryos (magenta bar) treated with the actin polymerization inhibitor Latrunculin B
(LatB, pink bar), Rac1 inhibitor CAS 1177865-17-6 (green bar), Trio inhibitor ITX3 (yellow bar). Right panel, RI upon indicated inhibitor treatment. Mean ±
s.e.m, one-way ANOVA, post-hoc bonferroni, n= 25, 38, 30, 60, 59 aISVs for indicated condition. ***p < 0.001. g–i aISV in WT (g), WT injected with 1.7 ng
Trio targeting morpholino (h), and WT injected with 5 ng Trio targeting morpholino (i). j–l aISV in plgfmusc (j), plgfmusc injected with 1.7 ng Trio targeting
morpholino (k), and plgfmusc injected with 5 ng Trio targeting morpholino (l). m Quantification of images in g–l. Mean ± s.e.m, ANOVA & post-hoc
bonferroni, n= 17, 21, 18, 15, 17, and 16 aISVs/group. ***p < 0.001. n–p aISV in WT (n), WT injected with 1.7 ng Trio targeting morpholino (o), and WT
injected with 5 ng Trio targeting morpholino (p). q–s aISV in plgfmusc (q), plgfmusc injected with 1.7 ng Trio targeting morpholino (r), and plgfmusc injected with
5 ng Trio targeting morpholino (s). t Quantification of images in n–s. Mean ± s.e.m, ANOVA & post-hoc bonferroni, n= 18, 14, 14, 16, 18, and 18 aISVs per
group. ns not significant, **p < 0.01, ***p < 0.001. Scale bar, 25 µm in all panels. aISV intersegmental artery, MO morpholino.
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diameters, and EC size, in WT and in plgfmusc embryos (Fig. 8v,
w, Supplementary Fig. 11g, h). In vitro, human aorta (HAEC) and
human umbilical artery derived endothelial cells (HUAEC)
showed a significantly increased size upon TrioN overxpression
(Supplementary Fig. 11f). As Vegf is the major driver of Trio
activation in our setting, we hypothesized that our findings
regarding enlargement may be conserved in other vegf gain of
function scenarios. Von Hippel Lindau (Vhl) is a protein relevant
for probing Hypoxia Inducible Factor-1α (HiF-1α), the main
driver of vegf expression, for proteasomal degradation. Vhl−/−
mutants show increased vegfaa expression, in particular in
developing neuronal tissue29. Accordingly, vhl−/− mutants
showed increased cerebral arterial diameters, without significant
change in endothelial cell numbers (Supplementary Fig. 11i–p).
Vhl morphants also showed increased vessel diameter, conco-
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Fig. 11q–u). Blocking Trio function using ITX3 inhibited the
diameter increase in vhl morphants (Supplementary Fig. 11s, u).
This suggests that Trio-mediated cell and vessel dimension
changes is conserved in this Vegf gain of function scenario.
In zebrafish embryos, loss of the TGFβ co-receptor endoglin
augments aortic diameter in response to flow increases10.
Morpholino-mediated loss of endoglin increased aorta diameter
at 3dpf, not 2dpf, in-line with the endoglin mutant phenotype
(Supplementary Fig. 12a–r, u). We found no evidence for loss of
endoglin and gain of Trio acting synergistically to influence aISV
or aortic diameters in 2dpf embryos (Supplementary Fig. 12a–i;
Supplementary Fig. 12j–r). In vitro, cell size of TrioN over-
expressing cells was not significantly different from the size of
TrioN expressing cells in which endoglin was silenced (Supple-
mentary Fig. 12s, t). At 3dpf endoglin morphants showed an
increased aorta diameter similar to the phenotype reported in
endoglin mutants (Supplementary Fig. 12u)10. Since in the
endoglin mutant the change in aorta diameter was attributed to
an increase in EC size and not EC number, we considered a
potential contribution of Trio in mediating the diameter increase.
Accordingly, loss of Trio in endoglin morphants, or inhibiting
Trio function using ITX3 in endoglin morphants inhibited the
aorta diameter increase and reduced EC surface area (Fig. 9a, b).
This suggests that at 3dpf the TGFβ pathway may act as an
inhibitor of Trio function and diameter control.
Discussion
Here we identified the GEF Trio as a central signaling hub in
driving endothelial cell enlargement and outward arterial lumen
diameter remodeling, downstream of Vegf receptor-2 signaling.
Endothelial cell enlargement requires the GEF1 domain of Trio,
and activation of the Trio-GEF1 targets Rac1 and RhoG, inducing
F-actin remodeling events, focal adhesions, and actomyosin ten-
sion specifically at the cell periphery. Actomyosin-activity
induced tension at extracellular matrix anchors in lamellipodia
extensions is subsequently conveyed into a homothetic expansion
of the endothelial cell. Actin remodeling in the endothelial cell
periphery requires activation of Rho GTPases specifically in
junctional regions. In line with this, we show that Trio activates
Rac1 in the cell periphery. Active Trio is expressed at junctional
regions, and Trio also directs other GEFs including Tiam1 to the
junctions. Tiam1 has thus far not been linked to Vegf receptor
signaling. Tiam1 is a known activator of Rac1, and we show that
Tiam1 promotes endothelial cell size, similar to Trio. Combining
Trio and Tiam1 overexpression has no additive effect on aug-
menting endothelial cell size, thus leaving open the option that
Trio and Tiam1 may act in a linear way to induce Rac1 activity at
junctional regions. Trio and Tiam1 are not the only GEFs that
can activate Rac1 and it is conceivable that activation of addi-
tional Rac1 pools, at different intracellular locations and coupled
to other downstream effectors, also contributes to the complex
process of cell enlargement.
Besides activation of Rac1, the GEF1 domain of Trio is also
recognized for its ability to exchange GTP on the related small
GTPase RhoG. Similar to Rac1, we show that RhoG gain-of-
function results in larger endothelial cells, while loss of RhoG
reduces Trio-induced cell size. How RhoG contributes to endo-
thelial cell size increase may however differ from Rac1, as RhoG is
dispensable for lamellipodia formation37. We noticed that upon
Trio activation, the distribution of the Integrins β1 and α5 shifted
from a well-known focal adhesion pattern towards a more
junctional pattern. Also Paxillin, a well-recognized marker for
focal adhesions shifted to the junction regions. Integrins may be
involved in the regulation of Trio-mediated increase in cell size by
controlling ECM contacts near junctions as a means to keep the
enlarged cell in its shape and preventing it from collapsing. RhoG
may contribute herein as it has been shown to modulate focal
adhesion turnover46 and microtubule dynamics, at least in cancer
cells and epidermal keratinocytes46–48. Vegf has also been shown
to activate RhoG independently of Trio49. Interestingly, here
RhoG subsequently activated Rac1 through the atypical GEF
DOCK4, whereas SGEF, instead of Trio, was the responsible
upstream activator of RhoG. Thus, downstream from VEGF,
SGEF, and Trio may work in parallel, to activate RhoG and Rac1,
respectively. Both pathways may also function as a reciprocal
backup, as it was reported that SGEF knock out animals do not
show any vascular malformations50.
Increasing Vegf—Trio signalling strength in developing arter-
ies and augmenting both arterial endothelial cell size and their
number allows for a 2–2.5-fold structural increase of arterial
lumen diameter in vivo (Fig. 10a, b). Using Vegf to obtain arterial
diameter growth in aISVs in vivo requires precise fine-tuning of
local Vegf signaling strength in arterial endothelium. This can be
achieved by targeting the arterial Flt1-Vegf binding equilibrium
with the Flt1 specific ligands Plgf and Vegfb. We demonstrate
that developing arteries express Flt1 protein, and analyses of flt1
mutants and flt1 morphants shows that arterial Flt1 traps suffi-
cient endogenous Vegf to modulate arterial diameter growth.
Overexpression of Plgf or Vegfb, and displacing the arterial Flt1-
trapped Vegf, results in an artery specific Vegf gain of function
scenario. This triggers an increase in arterial endothelial cell size
and number, culminating in a two-fold increase in arterial dia-
meter. Plgf-induced arterial diameter growth requires Vegfaa-
Kdrl signaling, but is independent of mFlt1 signaling, as the
Fig. 5 Trio-GEF1 domain targets Rac1 and RhoG increase endothelial cell size. a–f Confocal images showing mCherry (a, c, e) and F-actin distribution (b,
d, f) in ECs transfected with mCherry, mCherry-TrioN (TrioN), or mCherry-TrioGEF1 (TrioGEF1). Scale bar, 25 µm. g Endothelial cell surface area in ECs
expressing mCherry, mCherry-TrioN, or mCherry-TrioGEF1. Mean ± s.e.m, unpaired two-sided students t-test, n= 59, 69, 63 cells per indicated group. ***p <
0.001. h–k Confocal images of ECs transfected with mCherry, photo-activatable Rac1 (mCherry-Rac1-PA-WT), mutated photo-activatable Rac1 (mCherry-
Rac1-PA-C450A), or constitutively active Rac1 construct (mCherry-Rac1-Q61L). Red arrowheads indicate cell–cell junctions. Scale bar, 25 µm. l Quantification
of images in h–k. Mean ± s.e.m, two-sided Mann–Whitney U test, n= 67, 56, 65, 74 cells per group. *p= 0.0477, ***p < 0.001. m Surface area of ECs
transfected with control plasmid or constitutive active RhoG Q61L. Mean ± s.e.m, unpaired two-sided students t-test, n= 89, 83 cells per group, from three
independent experiments. ***p < 0.001. n Western blots for Rac1 and RhoG; control of knockdown efficiency for shRNA shRac1 and shRhoG as used in O, P
and actin for protein loading control, as indicated. o Change in EC size upon TrioN overexpression after silencing of Rac1. Mean ± s.e.m, unpaired two-sided
students t-test, n= 73, 97 cells from three independent experiments. ***p < 0.001. p Change in EC size upon TrioN overexpression after silencing of RhoG.
Mean ± s.e.m, unpaired two-sided students t-test, n= 101, 146 cells per group from three independent experiments. ***p < 0.001. q–s Endothelial cells
transfected with control plasmid (ctrl) and stained for Tiam1 (q), F-actin with phalloidin (r) and VE-Cadherin as junction marker (s). Tiam1 localizes
cytosolic and to a lesser extent to junction regions. Scale bar, 20 μm. t–v Endothelial cells transfected with TrioN and stained for Tiam1 (t), F-actin with
phalloidin (u) and VE-Cadherin as junction marker (v). Tiam1 localizes at junction regions (arrowheads). Scale bar, 20 μm. w Endothelial cell size of ECs
transfected with Tiam1, TrioN, or transfected with both Tiam1 and TrioN. Cell size was measured of n= 78, 82, 103 and 80 cells derived from three separate
experiments. Mean ± s.e.m, unpaired two-sided students t-test. ns not significant, ***p < 0.001.
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growth effect of Plgf is maintained in mflt1 mutants. Arterial
endothelial cells of aISVs enlarge considerably in plgfmusc trans-
genics. Consistent with Trio driving endothelial enlargement in
this Vegf gain of function scenario, we find that inhibiting Trio
reduces endothelial cell size, and aISV diameter in plgfmusc. Our
model suggests that arterial diameter growth in plgfmusc involves a
combination of both increased cell number and enlarged size,
enabling the shaping of a structurally larger lumen (Fig. 10a, b).
Trio gain- and loss-of-function experiments in WT and
plgfmusc embryos show that Trio augments arterial lumen
dimensions through modulation of endothelial cell shape. The
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autonomous manner. Trio furthermore augments junctional
integrity and stabilizes endothelial–endothelial cell–cell junctions.
Such increased junctional stability would be beneficial to keep
expanding vessels sealed and prevent plasma leakage during the
outward remodeling process45,51. The TGFβ co-receptor Endo-
glin controls arterial diameter in response to shear stress through
modulation of endothelial cell shape6,10. With respect to the
regulation of 2dpf aISV and aorta diameter, we find no interac-
tion between Vegf-Trio signaling and Endoglin. However,
observations in 3dpf aorta suggest that Trio may be required for
mediating aorta diameter increase upon loss of endoglin. How
loss of endoglin couples to Trio remains to be determined but
human endothelial cells devoid of Endoglin show altered VEGFR-
2 kinetics, and exhibit differential activation of VEGFR-2
downstream pathways, including AKT6. We hypothesize that
Vegf can activate Trio during early stages of arterial network
remodeling, whereas the TGF beta pathway may act to restrict
Trio function once flow becomes more dominant during the
maturation of the arterial network. Although we originally
investigated activation of Vegf-Trio as a means to augment
arterial diameter in the context of improving perfusion for
ischemic cardiovascular disease, the notion that inhibiting Trio
and reducing EC and arterial size, may have therapeutic relevance
as well for preventing shunt formation and vascular complica-
tions in, for example hereditary hemorrhagic telangiectasia
(HHT)10,11.
In early zebrafish embryos, mural cells are absent and vessel
size is determined solely by the endothelium. In adult resistance
sized arteries the presence of several layers of smooth muscle
cells, and sympathetic nerve induced vascular tone may restrict
the impact of Trio on diameter remodeling. It therefore seems
unlikely that activating Trio and promoting EC size, can directly
affect arterial diameter independent of vascular smooth muscle
function in mature resistance sized arteries. Flt1 and its ligands
PlGF and VEGF-B can regulate vascular adaptation in ischemic
cardiovascular conditions in mouse, rat and pig models52–56. In
rats, constitutive cardiomyocyte specific expression of full length
Vegf-b results in enlargement of all coronary arteries53. In the
coronaries, Flt1 and Kdr only colocalize in the most distal areas
and capillaries, whereas coronary arteries in the proximal part
express only Flt1. Based on the juxtapositioning of Flt1 and Kdr,
it is therefore conceivable that arterial enlargement commences in
precapillary arteries and that this is propagated retrogradely to
the proximal areas53. We previously showed that such retrograde
communication mechanism between micro- and macrocircula-
tion, exists in an ischemic setting and promotes arterial remo-
deling57. In a more physiological context, increases in metabolism
or tissue hypoxia can trigger the local release of Vegf. Vegf-Trio-
induced endothelial enlargement and diameter increase reduce
the resistance to flow. At a given pressure gradient this results in a
redistribution of flow toward the enlarged vessel segment in the
Vegf-producing or hypoxic region. We hypothesize that such
vessel adaptations allow matching of changes in metabolism with
flow delivery. We propose that this mechanism may operate in
particular in vessel segments that lack the ability to actively
regulate vascular tone by smooth muscle cells, which is typically
the case in the most distal parts of the microcirculation, the areas
where Flt1 and Kdr are co-expressed.
Methods
Ethics statement. Zebrafish husbandry and experimental procedures were per-
formed in accordance with local and national German animal welfare standards58
and were approved by the government of Baden-Württemberg, Regierung-
spräsidium Karlsruhe, Germany (Akz.: 35-9185.81/G-93/15; Akz.: 35-9185.81/G-
93/19), the government of Berlin, Regierungspräsidium Berlin, Germany (Akz.:
Reg0318/13) and the government of Nordrhein-Westfalen, Germany (Akz.: 81-
02.05.40.19.044).
Zebrafish maintenance and strains. Zebrafish were maintained at standard
conditions58. Embryos were incubated at 28.5 °C and staged by hours or days post
fertilization (hpf or dpf, respectively). The following zebrafish lines were used: Tg
(fli1a:EGFP)y1, TgBAC(flt1:YFP)hu4624, Tg(flt1enh:tdTomato)hu5333, TgBAC(flt4:
mCitrine)hu7135, Tg(kdrl:hsa.HRAS-mcherry)s916, Tg(fli1a:lifeactEGFP)mu240, Tg
(fli1a:nEGFP)y7, Tg(fli1ep:gal4ff)ubs4, Tg(UAS:VE-cadherinΔC-EGFP)ubs12, Tg
(mpeg1:GAL4-VP16)gl24, Tg(UAS:E1b:Kaede)s1999t, flt1ka601, flt1ka605, vhlhu2114,
cdh5ubs8 and nrp1ahu10012 as published29,59–68.
Generation of mutant and transgenic lines. Zebrafish embryos were injected at
the one-cell stage with a glass microneedle and a microinjector (World Precision
Instruments). For transgenesis tol2 mRNA, transcribed from pCS2FA with the
mMESSAGE mMACHINE SP6 Transcription Kit, a kind gift from Koichi Kawa-
kami, was injected at a concentration of 25 ng µl−1 together with Tol2 destination
vectors69. For mutagenesis Cas9 mRNA was in vitro transcribed from the
MLM3613 plasmid (Addgene plasmid #42251) using the mMESSAGE mMA-
CHINE T7 ULTRA Transcription Kit (Thermo Fisher Scientific); sgRNA target
sequences were cloned into DR274 (Addgene plasmid # 42250) and transcribed
with the MAXIscript T7 transcription kit (Thermo Fisher Scientific). Subsequently,
1 nl of a mixture of 600 ng ml−1 Cas9 mRNA and 50 ng ml−1 sgRNA were co-
injected into one-cell stage embryos29.
Generation of Vegfaa gain of function lines. In order to generate a constitutive
overexpression construct for vegfaa165 in skeletal muscle tissue, a Gateway reaction
using p5E_503unc, pME_GFP-p2A-vegfaa165, p3E_polyA, and pDestTol2CG2
was performed (Supplementary Fig. 1a). For constitutive overexpression 25 ng µl−1
of 503unc:eGFP-p2A_vegfaa were co-injected with tol2 transposase mRNA.
Embryos were identified by means of the transgenesis marker cmlc2:EGFP as well
as green fluorescence in the skeletal muscle tissue.
For inducible vegfaa165 gain of function, an inducible, muscle-specific
expression construct was generated in a Gateway reaction with p5E_503unc,
pME_gal4ERT2, p3E_polyA, and pDestTol2CG2; the other expression construct
Fig. 6 Trio activates Rac1 and induces tension in endothelial junctional regions. a EC transfected with mCherry and Rac1 biosensor (Cer3, cerulean3
channel) and stained for VE-Cadherin. FRET signals depicted as warm colors. b EC transfected with mCherry-TrioN and Rac1 biosensor (Cer3) and stained
for VE-Cadherin. FRET signals depicted as warm colors. Arrowheads indicate FRET signal in junctional regions. c, d Rac1 activation for indicated scenario.
Mean ± s.e.m, two-sided Mann–Whitney U test, n= 69, 59, 65, 69 cells per indicated group (c). Ratio junctional to cytoplasmic Rac1 activation (d): mean ±
s.e.m, two-sided Mann–Whitney-test, n= 69, 59, 65, 69 cells per group, respectively. ***p < 0.001. e Kymograph illustrating the actin cytoskeleton
dynamics along indicated line in control and TrioN-transfected cells. f Quantification of protrusion lifetime (left panel). Mean ± s.e.m, unpaired two-sided
students t-test, n= 50, 110 cells. (right panel) Quantification of protrusion dynamics expressed as protrusion number per hour from data in left panel.
***p < 0.001. g EC transfected with mCherry and GFP-Myosin II, stained for F-actin and VE-cadherin. Myosin-II localizes at actin bundles (arrowheads). h EC
transfected with mCherry-TrioN and GFP-Myosin II, stained for F-actin and VE-cadherin. Myosin-II localizes at junction actin bundles (arrowheads). i EC
transfected with GFP stained for pMLC-S19, F-actin, and VE-cadherin. j EC transfected with GFP-TrioN, stained for pMLC-S19, F-actin and VE-cadherin.
Arrowheads show pMLC-19 at junctional actin bundles. k EC transfected with GFP, stained for pMLC-T18S19 and F-actin. l EC transfected with GFP-TrioN,
stained for pMLC-T18S19 and F-actin. Arrowheads show pMLC-T18S19 at junctional regions. m, n distribution of F-actin (m) and VE-Cadherin (n) in TrioN
overexpressing EC. o Intracellular distribution of central, cortical and junctional F-actin bundles in ECs. p F-actin recoil response upon laser ablation. Shown
are pre-ablation (left panel) and post-ablation states (right panel); yellow arrowheads indicate the extent of recoil. q–s Recoil distance in central (q),
cortical (r) and junctional (s) F-actin bundles, in GFP and GFP-TrioN-transfected ECs; mean ± s.e.m, unpaired two-sided students t-test, n= 11, 7, 17, 13, 11
and 25 cells per indicated group. ns not significant ***p < 0.001. Scale bar, 25 µm in a, b, m, n; 20 µm in e, g–l, 10 µm in o, 5 µm in p.
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was produced using p5E_UAS, pME_GFP-p2A-vegfaa165, p3E_polyA and
pDestTol2CG2 (Supplementary Fig. 1b). 12.5 ng µl−1 of each of these two
constructs were co-injected with tol2 transposase mRNA. Vegfaa expression was
induced at 28 hpf by addition of 0.5 μM endoxifen in E3 medium (5 mM NaCl,
0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) and incubation of the embryos in
the dark.
Generation of an early stop flt4mutant allele. For the generation of the flt4mu407
allele via CRISPR-Cas9 genome editing, sgRNA synthesis was performed according
to the standard protocol70. The target sequence 5′-GGCTGTTATTGATGGC
ACCA-3′ resides in exon 3 and expanded a BsaJI restriction site, which was used
for screening and efficacy testing after PCR amplification using the primer pair 5′-
GAAGGAGTGTCAAGGGGTGG-3′ and 5′-CGGTTGCACATTCCCCAAAG-3′.
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flt4 sgRNA was injected into the cytoplasm of one-cell stage embryos. An 8 bp
deletion was identified by sequencing using previously indicated primers. The
deletion introduces a predicted premature stop codon within the first immu-
noglobulin domain (Ig) of the protein. Analysis of the thoracic duct (TD) at 5 dpf
revealed this allele to be phenotypically identical to the previously published
expando allele71.
Generation of the TgTm(flt1_E3_HAHA)ka611 knockin line. The knockin line
TgTm(flt1_E3_HAHA)ka611 was generated by injecting 600 ng µl−1 Cas9 mRNA
and 50 ng µl−1 sgRNAflt1Exon3 to induce a double strand break (DSB), together with
12.5 pg µl−1 oligonucleotide sFlt1_HAHA_ODN_1 (oligonucleotide sequences are
listed in Supplementary Table 2) for homologous recombination. The oligonu-
cleotide encodes two HA tags which are flanked by two 33 nt homology arms for
the flt1 genomic region surrounding the DSB (Supplementary Fig. 2f). Founders
were identified by the presence of an additional 60 bp larger PCR product,
amplified with flt1_E3_gDNA_fw and flt1_E3_gDNA_rev, and in-frame integra-
tion of the double HA tag was verified by Sanger sequencing of the PCR product.
The knockin line was viable, showed no vascular defects compatible with HA-
tagged Flt1 being functional.
Generation of the Tg(flt1enh:sflt1_Δ7-HAHA)ka612 line. For overexpression of
sFlt1 tagged with two HA tags, sflt1 was amplified with Phusion High-Fidelity
DNA polymerase (NEB) from cDNA with the primers Flt1_XhoI_fw and
sFlt1_HAHA_Xba and cloned into the MiniTol2 vector containing flt1 promoter/
enhancer elements (flt1enh)63 using the restriction enzymes XhoI and XbaI. The
resulting sflt1 overexpression construct flt1enh:sflt1_wt-HAHA (Supplementary
Fig. 2g, upper panel) was injected at a concentration of 12.5 ng µl−1 together with
25 ng µl−1 tol2 mRNA. Due to abrogation of ISV growth with this sflt1 over-
expression construct (Supplementary Fig. 2i–k), the Vegfaa binding site of sFlt1
was deleted (Supplementary Fig. 2h). Therefore, interface residues of the human
sFLT1 receptor domain 2 binding to human VEGF-A were identified with PyMOL
(www.pymol.org). The corresponding positions in the zebrafish sFlt1 homologue
were identified as E134 to Y140 (Supplementary Fig. 2h), encoded by the base pairs
403–423. These were deleted from flt1enh:sflt1_wt-HAHA by site-directed muta-
genesis (SDM) with the primers SDM_Flt1delta7_fw and SDM_Flt1delta7_rev. For
SDM the PCR product was phosphorylated with T4 polynucleotide kinase, fol-
lowed by blunt end ligation with T4 DNA ligase (both NEB). Remaining template
plasmid was digested with DpnI. 25 ng µl−1 of the resulting flt1enh:sflt1_Δ7-HAHA
Tol2 expression construct (Supplementary Fig. 2g, lower panel) were injected with
tol2 transposase mRNA, fish were raised and founders of the Tg(fltenh:sflt1_Δ7-
HAHA)ka612 line were identified by PCR using the primers sflt1_fw and HA_rev.
Generation of plgfmusc and vegfbamusc gain of function lines. For overexpression
of zebrafish plgf (ENSDART00000156625.2) and vegfba (ENSDART00000123364.3),
their coding sequences were cloned into Gateway middle entry clones. Therefore,
plgf and vegfba coding sequences were amplified with Phusion High-Fidelity DNA
polymerase (NEB) from zebrafish cDNA with SmaI_Plgf_CDS_fw/ XhoI_Plgf_CDS_
rev, and SmaI_Vegfba_CDS_fw/XhoI_Vegfba_CDS_rev, respectively (Supplementary
Table 2). The vector pME_eGFP-p2A_SmaI and the PCR products were digested with
SmaI and XhoI, and after gel purification ligation reactions were performed with T4
DNA ligase (NEB). The resulting middle entry clones pME_GFP-p2A-plgf and
pME_GFP-p2A-vegfba were used in Gateway reactions (Thermo Fisher Scientific, LR
clonase II plus) with p5e_503unc, p3E_polyA and pDestTol2CG2. For generating the
stable transgenic lines Tg(503unc:eGFP-p2A-plgf)ka613 (referred to as plgfmusc) and
Tg(503unc:eGFP-p2A-vegfba)ka614 (referred to as vegfbamusc) (Supplementary Fig. 2o,
p), 25 ng µl−1 overexpression constructs 503unc:eGFP-p2A-plgf or 503unc:eGFP-p2A-
vegfba were co-injected with tol2 transposase mRNA. Fish were raised and founders
were identified by means of the transgenesis marker cmlc2:EGFP as well as green
fluorescence in the skeletal muscle tissue.
Trio gain of function. TrioN contains the N-terminal part of Trio (amino acids 1-
1685) including the Sec14 domain, spectrin repeats, the Rac1/RhoG GEF1 domain
and SH3 domain, but excluding the RhoA-specific GEF2 domain and kinase
domain72. For TrioN overexpression under the flt1enh promoter in zebrafish
embryos, the p5E_flt1enh, pENTR1a_GFP-TrioN and p3E_polyA sequences were
recombined into the pDestTol2CG2 in a Gateway reaction (LR clonase II plus;
Thermo Fisher Scientific). The resulting expression construct was injected into the
cytoplasm of one-cell stage embryos at a concentration of 25 ng µl−1 together with
tol2 mRNA. For generation of the stable transgenic line Tg(flt1enh:GFP-TRION)
ka615 (referred to as flt1enh:TrioN), injected fish were raised and founders were
identified by means of the transgenesis marker cmlc2:EGFP. Overexpression of
TrioN under the kdrl and fli1a promoter in zebrafish embryos was performed
likewise via Gateway recombination reactions using the respective p5E_kdrl and
p5E_fli1a plasmids. The mutant GFP-TrioNmut construct (TrioNmut) was gen-
erated by site-directed mutagenesis of nucleotides 4399-4405 (NM007118) AAT-
GAC to GCTGCC. This results in the amino acid mutations N1406A and D1407A,
located in the C-terminus of the DH1 domain. The mutated GEF domain is still
able to bind Rac1, but unable to induce guanine nucleotide exchange. Over-
expression of TrioNmut under the flt1enh promoter was performed similarly to
TrioN. For Trio gain of function in vitro, primary HUVECs, which were acquired
from Lonza (Verviers, Belgium) and regularly checked for mycoplasma con-
tamination, were seeded on culture flasks. HUVECs were grown in EGM-2 med-
ium (Promocell, Heidelberg, Germany). Cells were cultured on fibronectin-coated
glass coverslips and transfected with human GFP-TrioN, mCherry-TrioN,
mCherry-TrioNmut, mCherry-TrioGEF1 or the isoform TrioB. The mCherry-
TrioN/TrioNmut/TrioGEF1 constructs were generated by replacing GFP in GFP-
TrioN/TrioNmut/TrioGEF1 with mCherry using AgeI and Kpn2I restriction
enzymes. After treatment, cells were washed with warm PBS, containing 1 mM
CaCl2 and 0.5 mM MgCl2, and fixed in 4% (v/v) formaldehyde for 10 min. After
fixation, cells were permeabilized in PBS supplemented with 0.1% (v/v) Triton X-
100 for 10 min followed by a blocking step in PBS supplemented with 2% (w/v)
BSA and stained as indicated45.
Rac1 gain of function. In vitro Rac1 gain of function experiments were performed
similarly to Trio gain of function approaches. pTriEx-mCherry-PA-Rac1 and
pTriEx-mCherry-PA-Rac1-C450A were a kind gift from Klaus Hahn (Addgene
plasmid # 22027: http://n2t.net/addgene:22027, RRID:Addgene_22027 and
Addgene plasmid # 22028: http://n2t.net/addgene:22028, RRID:Addgene_22028).
Cloning of mCherry-Rac1-Q61L and Rac1B was performed as previously
described39,73.
RhoG gain of function. In vitro RhoG gain of function experiments were per-
formed similarly to Trio & Rac1 gain of function approaches. GFP-RhoG Q61L was
a kind gift from Dr. Keith Burridge (UNC Chapel Hill, USA).
Fig. 7 Trio acts cell-autonomous to increase endothelial cell size. a Electrical Cell-Substrate impedance (ECIS) array in control and TrioN overexpressing
EC. Experiment in triplicate, repeated three independent times. Mean ± s.e.m, unpaired two-sided students t-test, ***p < 0.001. b ECIS array in control
plasmid or TrioN-transfected EC, and co-transfected with control shRNA or VE-Cadherin silencing shRNA. Experiment in duplicate, repeated three
independent times. Mean ± s.e.m, unpaired two-sided students t-test, **p= 0.0063, ***p < 0.001. c Relative impedance change for indicated scenario
based on data in b. Experiment carried out in duplicate, three independent times. Mean ± s.e.m, unpaired two-sided students t-test. ns not significant.
d–f VE-Cadherin (d), F-actin (e), and mCherry (f) distribution in EC transfected with mCherry plasmid and control shRNA (shCTRL). g–i VE-Cadherin (g),
F-actin (h), and mCherry-TrioN (i) distribution in ECs transfected with shCTRL, and co-transfected with TrioN. Arrowheads show colocalization of VE-
Cadherin, F-actin and TrioN at cell–cell junctions. j–l VE-Cadherin (j), F-actin (k), and mCherry-TrioN (l) distribution in ECs transfected with shVE-Cadherin,
and co-transfected with TrioN. Arrowheads show intact F-actin bundles and TrioN expression at junctions. m EC size for indicated scenario. mean ± s.e.m,
two-sided Mann–Whitney U test, n= 69, 26, and 22 cells per group derived from four independent experiments. ***p < 0.001. n EC size of TrioN expressing
cell, when in contact with TrioN expressing neighbouring cell (homogenous expression) or when in contact with control-transfected neighbouring cells
(mosaic expression). Cell-sizes from 52 cells per condition, and two independent experiments. Mean ± s.e.m, unpaired two-sided students t-test. ns not
significant, ***p < 0.001. o, p Distribution of focal adhesions, labeled with phospho-Paxillin (o); and F-actin (p) in control-transfected ECs. q, r Distribution
of focal adhesions, labeled with phospho-Paxillin (q); and F-actin (r) in TrioN-transfected ECs. s Focal adhesion density in control and TrioN-transfected
ECs. Mean ± s.e.m, unpaired two-sided students t-test, n= 7, 9 cells per indicated group. ***p < 0.001. t Integrin-alpha-5 and F-actin expression in GFP
control-transfected EC. u Integrin-alpha-5 and F-actin expression in GFP-TrioN-transfected EC. Arrowheads indicate junctional region. v Integrin-beta-1 and
F-actin expression in GFP control-transfected EC. w Integrin-beta-1 and F-actin expression in GFP-TrioN-transfected EC. Arrowheads indicate junctional
region. Scale bar, 25 μm in all panels.
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Fig. 8 Trio augments endothelial cell size and arterial diameter in vivo. a, b Imaging of aISV in WT (a) and in flt1enh:TrioN embryos (b). c, d EC nuclei
distribution in WT (c) and flt1enh:TrioN embryos (d). Note: six ECs in both scenarios and larger aISV diameter upon TrioN. e Quantification of aISV diameter
for indicated scenario. Mean ± s.e.m, two-sided Mann–Whitney U test, n= 35 aISVs per genotype. ***p < 0.001. f Quantification of EC surface area in aISVs
for indicated scenario. Mean ± s.e.m, two-sided Mann–Whitney U test, n= 34, 48 aISVs per indicated genotype. ***p < 0.001. g Quantification of EC nuclei
number in aISVs for indicated scenario. mean ± s.e.m, two-sided Mann–Whitney U test, n= 51, 70 aISVs per genotype. ns not significant. h–k aISV in WT
(h), in plgfmusc (i), plgfmusc combined with flt1enh:TrioN (j), and plgfmusc combined with flt1enh:TrioNmut (k). l–n Transverse optical section of aISV vessel
lumen in WT (l), plgfmusc (m), and plgfmusc+flt1enh:TrioN scenario (n). The lumen area is color indicated (lower panels). o Left panel: Quantification of aISV
diameter in WT, plgfmusc, plgfmusc+flt1enh:TrioN, and plgfmusc+flt1enh:TrioNmut scenario. Mean ± s.e.m, unpaired two-sided students t-test, n= 18, 19, 13, 14
aISVs per group. ns, not significant; ***p < 0.001. Right panel: Quantification of EC size in WT, plgfmusc, plgfmusc+flt1enh:TrioN, and plgfmusc+flt1enh:TrioNmut
scenario. Mean±s.e.m, unpaired two-sided students t-test, n= 21, 24, 15, 12 cells per group. ns not significant; ***p < 0.001. p–s aISV in WT embryo (p),
flt1enh:TrioN embryo (q), WT embryo injected with ve-cadherin (cdh5) targeting morpholino (r), flt1enh:TrioN embryo injected with ve-cadherin (cdh5)
targeting morpholino (s). t Quantification of images in p–s; mean ± s.e.m, unpaired two-sided students t-test, n= 15, 21, 16, and 13 cells per indicated
genotype. ***p < 0.001. u Dynamic changes in EC surface area in plgfmusc+ flt1enh:TrioN embryo, plgfmusc embryo, WT embryo injected with flt1 targeting
morpholino, and WT embryo. n= 12, 12, 10, 18 cells per indicated genotype, mean ± s.e.m. v, w Aorta diameter (v) and EC surface area (w) in kdrl:TrioN or
fli1a:TrioN scenario. Mean ± s.e.m, unpaired two-sided students t-test, n= 8, 10, 10 (v) and n= 8, 16, 14 (w) biologically independent embryos/group. *p <
0.05, **p= 0.0061. Scale bars: a–d, h–k, p–s, 25 μm, l–n 10 μm.
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Tiam gain of function. In vitro Tiam1 gain of function experiments were per-
formed similarly to RhoG gain of function approaches. HA-TIAM C1199 was a
kind gift from Dr. John Collard (NKI Amsterdam, Netherlands).
Further plasmids. Myosin IIA-GFP was a kind gift from Dr. Ana Pasapera
(NHLBI Bethesda, USA).
Morpholino knockdown. The following morpholino antisense oligomers (MOs;
Gene Tools) were injected into the yolk of one-cell stage embryos: 1 ng flt1 ATG
MO (5′-ATATCGAACATTCTCTTGGTCTTGC-3′); 4 ng flt4 ATG MO (5′-CT
CTTCATTTCCAGGTTTCAAGTCC-3′); 0.3 ng vegfaa ATG MO (5′-GTATCAA
ATAAACAACCAAGTTCAT-3′); 2.7 ng tnnt2 ATG MO (5′-CATGTTTGCTCT
GATCTGACACGCA-3′); a combination of 8.5 ng pu.1 ATG MO (5′-GATATA
CTGATACTCCATTGGTGGT-3′), 8.5 ng gcsfr ATG MO (5′-GAAGCACAAGCG
AGACGGATGCCAT-3′) and 10 ng irf8 splice-blocking MO (5′-AATGTTTCG
CTTACTTTGAAAATGG-3′) to inhibit macrophage formation; 0.8 ng, 1.7 ng,
3.3 ng, 5 ng and 8.4 ng trio ATG MO (5′-AGCTCATGGCTGACGAAAAAACA
CA-3′); 1.7 ng cdh5 ATG MO (5′-TTTACAAGACCGTCTACCTTTCCAA-3′);
5 ng endoglin (eng) ATG MO-1 (5′-AAACACAGCAGATGCTCTTCATGTC-3′);
5 ng eng ATG MO-2 (5′-GATGAACTCAACACTCGTGTCTGAT-3′); 6 ng, 3 ng
vhl E1 splice-blocking MO (5′-GCATAATTTCACGAACCCACAAAAG-3′); 10 ng
standard control MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′), all as
described29,74–78.
RNA interference. Inhibitory shRNA constructs (Supplementary Table 3) as well
as a non-targeting shCtrl (shC002) were packaged into lentivirus in HEK293T cells
by means of third generation lentiviral packaging plasmids. Lentivirus-containing
supernatant was harvested on day 2 and 3 after transfection. Lentivirus was con-
centrated via Lenti-X concentrator (Clontech). Target cells were infected and cells
were used for assays 3 days after virus infection.
RNA interference using siRNA constructs (Supplementary Table 4) was
performed as published37.
Chemical and inhibitor treatments. Embryos were dechorionated prior to che-
mical and inhibitor treatments using 1 mgml−1 Pronase (Roche, Basel, Switzer-




































































Fig. 9 Trio and endoglin interact to determine 3dpf aortic EC size. a Dorsal aorta diameter at 3dpf in endoglin morphants (magenta bar), endoglin
morphants injected with 0.8 ng Trio targeting morpholino (blue bar), endoglin morphants treated with Trio inhibitor ITX3 (dark green bar) and WT treated
with ITX3 (light green bar). Note that loss of Trio or inhibiting Trio reduced diameter growth in endoglin morphants. Mean ± s.e.m, unpaired two-sided
students t-test, n= 8, 9, 8, 10 independent embryos per group. **p= 0.0011, ***p= 0.001. b Aorta EC surface area at 3dpf in endoglinmorphants (magenta
bar), endoglinmorphants injected with 0.8 ng Trio targeting morpholino (blue bar), endoglinmorphants treated with Trio inhibitor ITX3 (dark green bar) and
WT treated with ITX3 (light green bar). Note that loss of Trio or inhibiting Trio reduced EC surface area in endoglinmorphants. Mean ± s.e.m, unpaired two-
sided students t-test, n= 18, 20, 22, 16 cells derived from six independent embryos per group; ***p < 0.001; **p= 0.0055; *p= 0.0100.








Lumen Multiple enlarged ECs
a
b
Fig. 10 Schematic representation of arterial lumen increase. a Increase in arterial lumen dimensions normalized to WT (WT= 1.0). Artery specific TrioN
gain of function fish show 1.5 fold, flt1 mutants show 1.6 fold, plgfmusc 1.9 fold, vegfbamusc 2.0 fold, and plgfmusc+artery specific TrioN 2.5-fold larger arterial
lumen diameter dimensions compared to WT. b Promoting endothelial cell enlargement results in larger arterial diameter. Simultaneously promoting
endothelial cell number and size, and creating arteries with multiple enlarged ECs results in even more pronounced arterial diameter increase.
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28.5 °C in the dark until the embryos were analysed at 50 hpf. For chemicals/
inhibitors dissolved in DMSO, control embryos were mock treated with DMSO
(Sigma). Inhibitor and chemical concentrations are listed in Supplementary Table 5
and 6. Embryos were randomly assigned to experimental groups. Investigators were
blinded to inhibitor treatment. In vitro chemical treatments were performed at
indicated time points. Inhibitor concentrations are further specified in Supple-
mentary Table 5.
Immunohistochemistry of zebrafish embryos. Fixed embryos were permeabi-
lized for 1 h in PBT (1% (v/v) Triton X-100 in 1x PBS). In order to reduce
unspecific background, samples were subsequently incubated for 2 h in blocking
buffer (1% (v/v) Triton X-100, 3% (w/v) BSA in 1× PBS). The primary antibody
(Supplementary Table 7) was diluted in 0.5% (v/v) Triton X-100, 1% (w/v) BSA in
1× PBS, and samples were incubated overnight at 4 °C. Embryos were washed five
times for 10 min with PBT before the secondary antibody (Supplementary Table 7)
was added for 2 h at room temperature. Before imaging, samples were washed five
times for 20 min in PBT.
Cell lines and immunofluorescent stainings in vitro. Antibodies used for
immunofluorescent staining of human endothelial cells in culture are indicated in
Supplementary Table 7. The following cell lines were used: Primary Human
Umbilical Vein Endothelial Cells (HUVECs, C2519A, Lonza); Primary Human
Umbilical Artery Endothelial Cells (HUAECs, isolated as described previously79)
and Primary Human Aortic Endothelial Cells (HAECs, CC-2535, Lonza). Cells
were routinely checked for mycoplasma contamination and authenticated by
immunofluorescence, flow cytometry and western blot for expression of standard
endothelial cell markers (VE-Cadherin, CD31, ICAM-1, VCAM-1, etc). Endothe-
lial cells were cultured in EGM-2 medium (Promocell, Heidelberg, Germany) up to
passage 5.
Whole mount in situ hybridization. Whole mount in situ hybridization was
performed with DIG labelled RNA probes. For generating the antisense ISH probe
of l-plastin, the plasmid, kindly provided by Philippe Herbomel, was linearized
with SpeI and transcribed with T7 RNA polymerase (Promega) and DIG labelling
mix (Roche). sflt1 and mflt1 antisense ISH probes were both linearized with SpeI
and transcribed with T7 RNA polymerase and DIG labelling mix. Embryos for
whole mount in situ hybridization were fixed in 4% (w/v) paraformaldehyde in 1×
PBS for 2 h at room temperature or overnight at 4 °C. After dehydration in 100%
methanol overnight at −20 °C, the embryos were rehydrated in a decreasing
methanol series, washed twice in PBT (1× PBS, 0.1% (v/v) Tween 20) and per-
meabilized using proteinase K at a concentration of 10 µg ml−1 in PBT. In order to
minimise unspecific background, embryos were prehybridized in hybridization mix
(50% (v/v) formamide; 5× SSC; 0.1% (v/v) Tween 20; 50 μg ml−1 heparin; 500 μg
ml−1 RNase-free tRNA) for 1 h at 65 °C. Embryos were then incubated with the
RNA probe in hybridization mix overnight at 65 °C. Next, the removal of the
formamid was obtained by a decreasing series of hybridization mix in 2× SSC at
65 °C, and a final washing step in 0.2× SSC at room temperature. Non-hybridized
RNA was removed using RNase A (Roth) in RNase buffer (HEPES 0.1 M pH 7.5;
NaCl 0.15M; 0.1% (v/v) Tween 20) for 45 min at room temperature, followed by a
washing step in 1× MAB-T (maleic acid buffer; 0.1% (v/v) Tween 20). Subse-
quently, nonspecific antibody binding sites were blocked by incubation in 2% (w/v)
Blocking Reagent (Roche) in 1× MAB-T, followed by incubation with alkaline
phosphatase-conjugated antibody (Anti-Dig, Fab fragments, 1:2.000, Roche)
overnight at 4 °C. Afterwards, embryos were washed once with 1× MAB-T and two
times for 15 min with NTMT (Tris-HCl 0.1 M pH 9.5; NaCl 0.1 M; 1% (v/v) Tween
20; MgCl2 50 mM). The in situ hybridization was developed with BM Purple
(Roche), a chromogenic substrate for alkaline phosphatase. When the staining
reaction was complete, embryos were washed with PBT and transferred to 80%
(v/v) glycerol in 1x PBS for microscopy and long-term storage.
Rac1 activity pull-down assay. Classical biochemical pull-down assays were
performed as described37. Briefly, a confluent monolayer of HUVECs was washed
with ice-cold PBS++ and subsequently lysed in lysis buffer (50 mM Tris, pH 7.4,
20 mM MgCl2, 500 mM NaCl, 1% (v/v) Triton X-100) supplemented with protease
inhibitors. Lysates were cleared at 14.000 Å ~ g for 5 min. GTP-bound Rac1 was
isolated with biotinylated Pak1-Crib peptide coupled to streptavidin agarose. Beads
were washed five times in wash buffer (50 mM Tris, pH 7.4, 10 mM MgCl2, 150
mM NaCl, 1% (v/v) Triton X-100) supplemented with protease inhibitors. Pull
downs and total cell lysates were immunoblotted with monoclonal Rac1, Trio and
beta-actin antibodies (Supplementary Table 7).
Western blotting. SDS-PAGE samples were analyzed on 7.5, 10, or 15% (w/v)
polyacrylamide gels, depending on the size of the proteins of interest, and trans-
ferred onto nitrocellulose membranes (Whatman, Piscataway, NJ). Subsequently of
blocking in 5% (w/v) low-fat milk in Tris-buffered saline Tween 20 (TBST), the
blots were incubated with respective primary antibodies (Supplementary Table 7)
for 1 h at room temperature, washed in TBST and incubated with respective HRP-
coupled secondary antibodies (Supplementary Table 7) for 1 h at room tempera-
ture. Blots were developed via enhanced chemiluminescence (ECL) (Thermo-
Scientific, Etten-Leur, The Netherlands). For Trio protein expression, 3–8% (w/v)
Tris-acetate precast gels (ThermoFisher) were used according to the manufacturer’s
instructions, and samples were transferred onto nitrocellulose membranes by
blotting for 18 h at 20 mA. Full Western blots in Supplementary Fig. 13.
Laser ablation. For laser ablation experiments HUVECs were transduced with
LifeAct-mScarlet expressing lentiviral particles. The 442 nm laser was used to
locally cut specific F-actin bundles. F-actin bundles were ablated for 10 seconds
using full laser power and retracted beam expander to concentrate the laser beam
intensity. Initial recoil of the cut F-actin bundles was measured immediately after
ablation.
Confocal microscopy. Zebrafish larvae were embedded in 0.7% (w/v) low-melting
agarose (NuSieve GTG Agarose, Lonza) in 35 mm glass bottom microscopy dishes
(MatTek). The agarose was covered with E3 medium supplemented with 0.112 mg
ml−1 Tricaine and 0.003% (w/v) PTU (Sigma). Confocal t- (for time-lapse ima-
ging) and z-stacks were acquired using a Leica SP8 confocal microscope with ×20
multi-immersion and ×40 water immersion objectives, resonance scanner, HyD
detectors and LAS X software. Images are displayed as maximum intensity pro-
jections of the z-stacks. For imaging of red blood cell perfusion, six images
per second were acquired at a single sagittal plane in the middle of the aISVs with
the SP8 confocal microscope. The transmitted light channel was used for the red
blood cells and the mCherry channel for the Tg(kdrl:hsa.HRAS-mcherry)s916 signal
marking the endothelial cell membranes. Images were processed with ImageJ/ Fiji.
aISV numbers are indicated in figure legends. For cell culture experiments, t- and
z-stack image acquisition was performed on a confocal laser scanning microscope
(Leica SP8) using a ×40 NA 1.3 or ×63 NA 1.4 oil immersion objective and LAS X
software. Maximum intensity projections were also generated and analyzed using
ImageJ/ Fiji software.
Transmitted light microscopy. Zebrafish larvae were anaesthetized in 0.112 mg
ml−1 Tricaine and transferred to E3 medium in a glass bottom microscopy dish.
Red blood cell perfusion was visualized by imaging a single sagittal plane in the
middle of two ISVs using a Zeiss Axioskop 5 microscope with ×40 objectives and
×4 optical gain for 40 ms exposure time.
Microangiography. Embryos were anaesthetized with 0.112 mgml−1 Tricaine in
E3 medium and mounted in 0.7% (w/v) low-melting agarose (NuSieve GTG
Agarose, Lonza) in glass bottom microscopy dishes (MatTek). For the micro-
angiography Texas Red-dextran with a molecular weight of 70 kDa (Thermo Fisher
Scientific, Supplementary Table 6) was solubilized in E3 medium to a concentra-
tion of 2 mgml−1. Using a glass microneedle and a microinjector (World Precision
Instruments), the dextran was injected into the sinus venosus. Subsequently,
images were taken with an SP8 confocal microscope (Leica).
Measurements of aISV diameter, DA diameter, endothelial cell sizes, and
numbers. For vessel parameter measurements, confocal z-stacks of ISVs plus
dorsal aorta were acquired of up to five aISVs per animal in the middle of the yolk
sac elongation and parameters were measured with Fiji using maximum projection
images of the z-stacks. For aISV diameter analysis, lateral lines were drawn at seven
evenly distributed positions along the aISV perpendicularly to the vessel wall
between the dorsal aorta and the DLAV, approximately every 18 µm. The average
of these seven lines was calculated as the average aISV diameter. The remodeling
index (RI) was calculated as follows: RI= (aISV diameter of the respective treat-
ment group in µm)/(average aISV diameter of the WT control group). For zeb-
rafish mutants and transgenic lines more than 50 embryos derived from more than
three different breedings were analysed per genotype. In morpholino experiments
morphologically malformed embryos were excluded from analysis. To determine
the dorsal aorta diameter, seven to nine vertical lines were drawn at ISV sprouting
positions and between two ISVs perpendicularly to the aortic vessel wall at the level
of the yolk sac elongation. The average of these lines per embryo was calculated as
average dorsal aorta diameter. Endothelial cell sizes in the zebrafish embryo were
visualized with the Tg(fli1a:lifeactEGFP)mu240 line. Endothelial cell outlines were
traced with the polygon selection tool in Fiji and the resulting area was measured.
Endothelial cell numbers were visualized with the Tg(fli1a:nEGFP)y7 line. For
in vitro experiments, cell size was determined either manually or by using a MatLab
script (MATLAB, The MathWorks, Inc., Natick, Massachusetts, United States).
Rac1 FRET biosensor analysis. The DORA Rac1 FRET-based biosensor was a
kind gift from Y. Wu (University of Connecticut Health Center, Farmington, CT).
Development and characterization of the DORA single-chain Rac1 biosensor are
described in more detail elsewhere45. Briefly, dimeric cerulean3 coupled to the Rac1
effector p21-activated protein kinase (PAK) is linked via ribosomal protein-based
linker (L9H) to circular-permutated Venus coupled to Rac1. HUVECs were
transfected with the Rac1 biosensor via electroporation using the Neon transfection
system (Life Technologies, one pulse, 1300 V, 30 ms) and used 24 h post trans-
fection. A Zeiss Observer Z1 microscope equipped with a ×40/numerical aperture
1.3 oil immersion objective, an HXP 120-V excitation light source, a Chroma 510
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DCSP dichroic splitter, and two Hamamatsu ORCA-R2 digital charge-coupled
device cameras was used for simultaneous monitoring of Cer3 and Venus emission.
Zeiss Zen 2012 microscope software was used to control the system. Offline ratio
analyses between Cer3 and Venus images were processed using the MBF ImageJ
collection. Image stacks were background corrected, subsequently aligned, and a
smooth filter was applied to both image stacks to improve image quality by noise
reduction. An image threshold was applied exclusively to the Venus image stack,
converting background pixels to “not a number (NaN),” eliminating artefacts in
ratio image derived from the background noise. Finally, the Venus/Cer3 ratio was
calculated with high activation shown in red/white and low activity in blue/black.
For FRET quantification, data were analysed using a MatLab script (MATLAB, The
MathWorks, Inc., Natick, Massachusetts, United States). Prior to any of the
ratiometric FRET analyses, donor CFP and acceptor YFP channels were back-
ground corrected by subtracting the modal pixel value, and both channels were
aligned to each other. Prior to watershed segmentation, cells were manually
selected by adding seed points and touching cells were separated by manually
drawing boundaries between them. A local threshold was applied to the watershed
region, exclusively including pixels that were higher than 15% of the maximum
intensity in that region. For all channels the mean fluorescence intensity was
calculated for each segmented region. Ratiometric FRET analysis was applied to
each segmented region in the cell. The endothelial junction marker VE-cadherin
was used as positive control. Quantification of FRET signal overlapping with VE-
cadherin was done between the cells edge and 10 pixels inwards. These areas were
defined as junction regions.
Resistance measurements. Monolayer integrity was determined by measuring
the electrical resistance using ECIS as published37. Electrode-arrays (8W10E;
IBIDI, Planegg, Germany) were treated with 10 mM l-cysteine (Sigma) for 10 min
and subsequently coated with 10 μg/ml fibronectin (Sigma) in 0.9% NaCl for 1 h at
37 °C. Cells were seeded at 40.000 cells per well (0.8 cm2) and grown to confluence.
Electrical resistance was continuously measured at 4000 Hz at 37 °C under 5% CO2
using ECIS model 9600 (Applied BioPhysics, New York, MA).
Focal adhesion quantification. Phospho-Paxillin-positive (pY118, Supplementary
Table 7) focal adhesions were quantified on thresholded images by analysing
particles sized between 0.5–10 µm2.
Statistical analysis and reproducibility. Statistical analysis was performed using
GraphPad Prism 6. Each dataset was tested for normal distribution with the
D’Agostino-Pearson test. Only if the data were normally distributed, a parametric
method (unpaired two-sided Students t-test) was applied. A nonparametric test
(two-sided Mann–Whitney test) was applied for non-normally distributed data
sets. In case of multiple comparisons, one-way ANOVA plus Bonferroni correction
or 2-way ANOVA were applied. P values < 0.05 were considered significant. Data
are represented as mean ± s.e.m., unless otherwise indicated. *P < 0.05, **P < 0.01
and ***P < 0.001, #P < 0.001 to indicated ctrl group. No data were excluded from
statistical analysis. No statistical method was used to predetermine sample size. For
every treatment, treated and control embryos were derived from the same egg lay;
embryo were selected on the following pre-established criteria: normal morphol-
ogy, a beating heart and circulating red blood cells. All images shown in the figures
are representative examples of the respective phenotypes and expression patterns.
The following section indicates how often experiments have been repeated inde-
pendently with similar results. Figure 1a, b, representative micrographs from n=
48, and n= 32 independent embryos per indicated condition. Figure 1c, d, images
are representative for n= 24 embryos per condition examined over three inde-
pendent experiments. Figure 1h–k, n= 112, 86, 126, 93 aISVs per genotype derived
from four autonomous experiments. Figure 1l, mean ± s.e.m, unpaired two-sided
students t-test, n= 18, 16, 16, 10 aISVs per genotype. ***p < 0.001. Figure 1m, n=
56 aISVs examined over three independent experiments. Figure 1n, mean ± s.e.m,
unpaired two-sided students t-test, n= 20, 25 aISVs for indicated scenario, ***p <
0.001. Figure 1o, p, plasma extravasation in WT (n= 14) and plgfmusc (n= 16
embryos) injected from three independent experiments. Figure 1q, mean ± s.e.m;
unpaired two-sided students t-test, n= 6, 8 embryos per indicated group. ns, not
significantly different. Figure 2d, mean ± s.e.m, unpaired two-sided students t-test,
n= 7, 13, and 24 aISVs for indicated scenario. **p= 0.0051, ***p < 0.001.
Figure 2e–g, representative image of indicated scenario (n= 40, 19, 13, respec-
tively). Figure 2h, mean ± s.e.m, unpaired two-sided students t-test, n= 40, 19, and
13 aISVs for indicated scenario, from three independent experiments. ns, not
significant. **p < 0.01. Figure 3a–d, representative micrographs from three inde-
pendent experiments. Figure 3e, mean ± s.e.m, one-way ANOVA and post-hoc
bonferroni test, n= 18, 20, 20, 15, 20, 20 aISVs for indicated scenarios. **p=
0.0026, ***p < 0.001. Figure 3f, mean ± s.e.m, one-way ANOVA and post-hoc
bonferroni test, n= 15, 22, 14, 28 aISVs for indicated scenarios. ***p < 0.001.
Figure 3k, n= 21, 16, 42, 34 aISVs per indicated genotype, mean ± s.e.m, unpaired
two-sided students t-test. ns, not significant, ***p ≤ 0.001. Figure 3l, m, repre-
sentative micrographs from 83 and 94 images, from three independent experi-
ments. Figure 3n, mean ± s.e.m, unpaired two-sided students t-test, n= 16 aISVs/
group. ***p < 0.001. Figure 3o–q, representative micrographs from n= 48, 55, 57
images per condition, from three independent experiments. Figure 3r, mean ± s.e.
m, unpaired two-sided students t-test, n= 11, 20, and 15 aISVs per treatment
group. ***p < 0.001. Figure 3v, mean ± s.e.m, unpaired two-sided students t-test, n
= 20 aISVs per group. ***p < 0.001. Figure 4a, b, n= 6 independent embryos per
group. Figure 4c, mean ± s.e.m, unpaired two-sided students t-test, n= 10, 11
aISVs for indicated genotype. *p= 0.0190, ***p < 0.001. Figure 4d, illustrations are
representative for each four independent embryos. Figure 4e, mean ± s.e.m,
unpaired two-sided students t-test, n= 6 ECs for each genotype. Surface area
expansion velocity is indicated as average slope (in μm2 h−1) calculated from
regression analysis. Figure 4f, mean ± s.e.m, one-way ANOVA and post-hoc bon-
ferroni test, n= 25, 38, 30, 60, 59 aISVs for indicated condition. ***p < 0.001.
Figure 4g–i, n= 67, 59, 60 aISVs examined over three independent experiments.
Figure 4j–l, n= 53, 48, 62 micrographs from three independent experiments.
Figure 4m, mean ± s.e.m, one-way ANOVA and post-hoc bonferroni test, n= 17,
21, 18, 15, 17, and 16 aISVs per group. ***p < 0.001. Figure 4n–p, n= 58, 58, 59
aISVs examined over three independent experiments. Figure 4q–s, n= 66, 58, 59
aISV micrographs per condition from three independent experiments. Figure 4t,
mean ± s.e.m, one-way ANOVA and post-hoc bonferroni test, n= 18, 14, 14, 16,
18, and 18 aISVs per group. ns, not significant, **p < 0.01, ***p < 0.001.
Figure 5a–f, images are representative for n= 120 ECs per group derived from
three independent experiments. Figure 5g, mean ± s.e.m, unpaired two-sided stu-
dents t-test, n= 59, 69, 63 cells per indicated group, respectively. ***p < 0.001.
Figure 5h–k, images are representative for n= 130 ECs per indicated group derived
from three biologically independent experiments. Figure 5l, mean ± s.e.m, two-
sided Mann–Whitney U test, n= 67, 56, 65, 74 cells per indicated group, respec-
tively. *p= 0.0477; ***p < 0.001. Figure 5m, mean ± s.e.m, unpaired two-sided
students t-test, n= 89, 83 cells per indicated group respectively, derived from three
independent experiments. ***p < 0.001. Figure 5o, mean ± s.e.m, unpaired two-
sided students t-test, n= 73, 97 cells per indicated group, examined over three
independent experiments. ***p < 0.001. Figure 5p, mean ± s.e.m, unpaired two-
sided students t-test, n= 101, 146 cells per indicated group examined over three
independent experiments. ***p < 0.001. Figure 5q–s, images are representative for
n= 120 ECs per group derived from three separate experiments. Figure 5t–v,
images are representative for n= 120 ECs per group derived from three biologically
independent experiments. Figure 5w, cell size was measured of n= 78, 82, 103, and
80 cells for indicated scenario, respectively, derived from three separate experi-
ments. Mean ± s.e.m, unpaired two-sided students t-test. ns, not significant, ***p <
0.001. Figure 6a, images are representative for n= 100 cells per group of three
independent experiments. Figure 6b, images are representative for n= 115 cells per
group of three independent experiments. Figure 6c, d, mean ± s.e.m, two-sided
Mann–Whitney U test, n= 69, 59, 65, 69 cells per indicated group (c). mean ±
s.e.m, two-sided Mann–Whitney U test, n= 69, 59, 65, and 69 cells per group (d).
***p < 0.001. Figure 6e, images are representative for n= 60 cells per condition
derived from threee independent experiments. Figure 6f, (left panel) mean ± s.e.m,
unpaired two-sided students t-test, n= 50, 110 cells per group. (right panel) mean
± s.e.m, unpaired two-sided students t-test, n= 50, 110 cells per group. ***p <
0.001. Figure 6g, images are representative for n= 90 cells derived from three
separate experiments. Figure 6h, images are representative for n= 90 cells derived
from three independent experiments. Figure 6i, images are representative for n=
120 cells derived from three individual experiments. Figure 6j, images are repre-
sentative for n= 120 cells derived from three separate experiments. Figure 6k,
images are representative for n= 120 cells derived from three independent
experiments. Figure 6l, images are representative for n= 120 cells derived from
three separate experiments. Figure 6m, n, images show representative phenotypes
of n= 160 cells out of four autonomous experiments. Figure 6o, image is a
representative scheme derived from n= 160 cells out of four autonomous
experiments. Figure 6p, images are representative for all indicated numbers of ECs
analyzed in 6q–s, examined over three independent experiments. Figure 6q–s,
mean ± s.e.m, unpaired two-sided students t-test, n= 11, 7, 17, 13, 11, and 25 cells
per indicated group. ns, not significant ***p < 0.001. Figure 7a, experiment was
carried out in triplicate, three independent times. Mean ± s.e.m, unpaired two-sided
students t-test, ***p < 0.001. Figure 7b, experiment was carried out in duplicate,
three independent times from each other. Mean ± s.e.m, unpaired two-sided stu-
dents t-test, **p= 0.0063, ***p < 0.001. Figure 7c, experiment was carried out in
duplicate, three independent times from each other. Mean ± s.e.m, unpaired two-
sided students t-test. ns, not significant. Figure 7d–f, images are representative for
n= 120 cells per condition derived from four independent experiments.
Figure 7g–i, images are representative for n= 120 cells per condition examined
over four independent experiments. Figure 7j–l, images are representative for n=
120 cells per condition derived from four independent experiments. Figure 7m,
mean ± s.e.m, two-sided Mann–Whitney U test, n= 69, 26, and 22 cells per group
derived from four independent experiments. ***p < 0.001. Figure 7n, determined
were the cell sizes of n= 52 cells per condition in two separate experiments. Mean
± s.e.m, unpaired two-sided students t-test. ns, not significant, ***p < 0.001. Fig-
ure 7o, p, images are representative for n= 100 cells per condition derived from
three independent experiments. Figure 7q, r, images are representative for n= 100
cells per condition derived from three independent experiments. Figure 7s, mean ±
s.e.m, unpaired two-sided students t-test, n= 7, 9 cells per indicated group. ***p <
0.001. Figure 7t, images are representative for n= 130 cells examined over three
autonomous experiments. Figure 7u, images are representative for n= 130 cells
examined over three autonomous experiments. Figure 7v, images are representative
for n= 130 cells examined over three independent experiments. Figure 7w, images
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19008-0
18 NATURE COMMUNICATIONS |         (2020) 11:5319 | https://doi.org/10.1038/s41467-020-19008-0 | www.nature.com/naturecommunications
are representative for n= 130 cells examined over three independent experiments.
Figure 8a, b, images are representative for n= 80 aISVs per genotype examined
over four separate experiments. Figure 8c, d, images are representative for n=
76,75 aISVs per genotype examined over three independent experiments. Figure 8e,
mean ± s.e.m, two-sided Mann–Whitney U test, n= 35 aISVs per genotype, ***p
< 0.001. Figure 8f, mean ± s.e.m, two-sided Mann–Whitney U test, n= 34, 48 aISVs
per indicated genotype, ***p < 0.001. Figure 8g, mean ± s.e.m, two-sided
Mann–Whitney U test, n= 51, 70 aISVs/genotype. ns, not significant. Figure 8h–k,
images are representative for n= 96, 83, 72, 79 examined aISVs per genotype
derived from three independent experiments. Figure 8l–n, images are representa-
tive for n= 116, 103, 112 examined aISVs per genotype. Figure 8o, (left panel)
mean ± s.e.m, unpaired two-sided students t-test, n= 18, 19, 13, 14 aISVs per
indicated genotype. ns, not significant; ***p < 0.001; (right panel) mean ± s.e.m,
unpaired two-sided students t-test, n= 21, 24, 15, 12 cells per genotype. ns, not
significant; ***p < 0.001. Figure 8p–s, images are representative for n= 84, 78, 89,
92 aISVs per condition. Figure 8t, mean ± s.e.m, unpaired two-sided students t-test,
n= 15, 21, 16, and 13 cells per indicated genotype, ***p < 0.001. Figure 8u, n= 12,
12, 10, 18 cells per indicated genotype, mean ± s.e.m. Figure 8v, w, mean ± s.e.m,
unpaired two-sided students t-test, n= 8, 10, 10 (v) and n= 8, 16, 14 (w) embryos
per group. *p < 0.05, **p= 0.0061. Figure 9a, mean ± s.e.m, unpaired two-sided
students t-test, n= 8, 9, 8, 10 embryos per group. **p= 0.0011; ***p= 0.0001.
Figure 9b, mean ± s.e.m, unpaired two-sided students t-test, n= 18, 20, 22, 16 cells
derived from six biologically independent embryos per group; ***p < 0.001; **p=
0.0055; *p= 0.0100.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its Supplementary files or from the corresponding author upon reasonable
request.
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